Display options
Cite
Verhulst K, Artiles-Carloni L, Beck M, et al. Source document verification in the Mucopolysaccharidosis Type I Registry. Pharmacoepidemiol Drug Saf. 2011;21(7):749-752doi: 10.1002/pds.2200.
Verhulst, K., Artiles-Carloni, L., Beck, M., Clarke, J. T., Neto, J. C., Cox, G. F., Fernhoff, P. M., Guffon, N., Kong, Y., Martins, A. M., Tylki-Szymanska, A., Whitley, C. B., Wijburg, F. A., Wraith, E. J., & Koepper, C. M. (2012). Source document verification in the Mucopolysaccharidosis Type I Registry. Pharmacoepidemiology and drug safety, 21(7), 749-752. https://doi.org/10.1002/pds.2200
Verhulst, Karien, et al. "Source document verification in the Mucopolysaccharidosis Type I Registry." Pharmacoepidemiology and drug safety vol. 21,7 (2012): 749-752. doi: https://doi.org/10.1002/pds.2200
Verhulst K, Artiles-Carloni L, Beck M, Clarke JT, Neto JC, Cox GF, Fernhoff PM, Guffon N, Kong Y, Martins AM, Tylki-Szymanska A, Whitley CB, Wijburg FA, Wraith EJ, Koepper CM. Source document verification in the Mucopolysaccharidosis Type I Registry. Pharmacoepidemiol Drug Saf. 2012 Jul;21(7):749-752. doi: 10.1002/pds.2200. Epub 2011 Dec 14. PMID: 22170853.
Copy Download .nbib Format: NLM
Share it on

Pharmacoepidemiol Drug Saf. 2012 Jul;21(7):749-752. doi: 10.1002/pds.2200. Epub 2011 Dec 14.

Source document verification in the Mucopolysaccharidosis Type I Registry.

Pharmacoepidemiology and drug safety

Karien Verhulst, Laura Artiles-Carloni, Michael Beck, Joe T R Clarke, Jordao Correa Neto, Gerald F Cox, Paul M Fernhoff, Nathalie Guffon, Yuan Kong, Ana Maria Martins, Anna Tylki-Szymanska, Chester B Whitley, Frits A Wijburg, Edward J Wraith, Catherine M Koepper

Affiliations

  1. Genzyme Europe BV, Naarden, the Netherlands.

PMID: 22170853 DOI: 10.1002/pds.2200

Abstract

PURPOSE: The Mucopolysaccharidosis Type I (MPS I) Registry is an international observational database that tracks the natural history and the outcomes of patients with MPS I. The Registry was a regulatory requirement following the approval of laronidase enzyme replacement therapy for MPS I in 2003. All data are collected voluntarily after informed consent from the patient or family. Data are checked through queries, monthly reviews, and electronic audits to identify missing, inconsistent, or invalid data. This analysis sought to determine overall data accuracy in the Registry through source document verification (SDV). METHODS: Two phases of SDV were performed. In each phase, Registry data were compared against source documents at sites in Europe, Latin America, and North America. Three patients were randomly selected for SDV at each of the selected sites among all patients enrolled ≥18 months and ever receiving laronidase. Key parameters central to MPS I and its treatment were examined from the baseline and the last available assessments. RESULTS: Results indicate an overall source-to-database error rate in the MPS I Registry of 2.7% (47 discrepancies out of 1715 items; 95% confidence interval [2.2%, 3.5%]) in Phase 1 and 3.7% (64 discrepancies out of 1732 items; 95% confidence interval [2.9%, 4.7%]) in Phase 2. No systematic errors were found. CONCLUSIONS: The overall error rates in both phases of SDV demonstrate acceptable data accuracy in the MPS I Registry within the data fields that were assessed. Copyright © 2011 John Wiley & Sons, Ltd.

Copyright © 2011 John Wiley & Sons, Ltd.

Publication Types